Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer.
Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer.
复制标题
新辅助 EGFR-TKI 对非小细胞肺癌患者疗效和安全性的现有证据
DOI：
10.3389/fonc.2021.608608
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Cai K
中科院分区：
文献类型：
--
作者：
Shi X;Dong X;Zhai J;Liu X;Lu D;Ni Z;Wu H;Cai K
Purpose Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been indicated to be an effective treatment for advanced EGFR-mutant NSCLC. However, the neoadjuvant application of EGFR-TKIs in resectable NSCLC needs further investigation. Here, we aimed to evaluate the efficacy and safety of neoadjuvant EGFR-TKIs for lung cancer. Methods Published studies on neoadjuvant EGFR-TKIs in NSCLC were identified in PubMed, Web of Science, and EMBASE until June 1, 2020. Data on surgical rates, objective response rates (ORRs), pathologic responses, and adverse event (AE) rates were retrieved for proportional meta-analysis. Results In total, 7 enrolled studies involving 129 EGFR-TKI-sensitive NSCLC patients were included in this analysis. The overall surgical rate in these studies was 95% (95% CI: 83% to 100%), with an ORR of 48% (95% CI: 39% to 57%) in the population with EGFR-TKI-sensitive mutations, whereas the ORR including wild-type EGFR patients was 28% (95% CI: 14% to 44%). The rate of grade 1-2 AEs was 69% (95% CI: 41% to 91%) but with an acceptable rate of grade 3-4 AEs of 0% (95% CI: 0% to 5%). The pooled rates of rash and diarrhea were 56% (95% CI: 31% to 79%) and 25% (95% CI: 6% to 51%), respectively. The impact of neoadjuvant EGFR-TKIs on survival remains inconclusive. Conclusions Neoadjuvant EGFR-TKIs showed objective responses in approximately half of EGFR-sensitive NSCLC patients with a tolerable adverse effect profile. The favorable impact of neoadjuvant EGFR-TKIs on NSCLC needs more evidence for validation, such as the comparison of survival improvement between EGFR-TKIs and chemotherapy. The efficacy of neoadjuvant next-generation EGFR-TKIs in clinical trials remains unclear.
登录
查看更多内容
DOI：
10.1097/jto.0b013e3181f38f70
发表时间：
2010-11
期刊：
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
影响因子：
--
作者：
Haura EB;Sommers E;Song L;Chiappori A;Becker A
通讯作者：
Becker A
影响因子：
2.5
作者：
Tierney JF;Stewart LA;Ghersi D;Burdett S;Sydes MR
通讯作者：
Sydes MR
影响因子：
51.1
作者：
Zhou, Caicun;Wu, Yi-Long;You, Changxuan
通讯作者：
You, Changxuan
影响因子：
20.4
作者：
Goldstraw, Peter;Chansky, Kari;Bolejack, Vanessa
通讯作者：
Bolejack, Vanessa
影响因子：
45.3
作者：
Schaake, Eva E.;Kappers, Ingrid;Klomp, Houke M.
通讯作者：
Klomp, Houke M.